all report title image

ANTI BETA ALZHEIMER THERAPIES MARKET ANALYSIS

Anti Beta Alzheimer Therapies Market, by Drug (Aducanumab, Bapineuzumab, Solanezumab), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Nov 2024
  • Code : CMI1204
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Anti Beta Alzheimer Therapies MarketSize and Trends

Market Trends

A breakthrough therapy is expected to provide immense growth for the Anti Beta Alzheimer Therapies Market

In July 2015, Biogen Pharmaceuticals announced results from a prespecified interim analysis of PRIME, which was the Phase 1b placebo-controlled study of aducanumab in patients with prodromal or mild Alzheimer’s disease (AD). Phase I clinical trials were conducted on 166, patients, which showed significant progress by lowering of Amyloid beta levels in the brain and slowdown in cognitive function as compared to the control group who received placebo. Phase III efficacy trial showed significant cognitive results in FDA based specific memory tests. On the other hand, in 2016, Eli Lilly and Company announced the development of Alzheimer drug solanezumab, which was in phase III clinical trial due to its slow progression of the Alzheimer disease and high cost.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.